Norway Onychomycosis Market Size & Outlook, 2025-2033
Related Markets
Norway onychomycosis market highlights
- The Norway onychomycosis market generated a revenue of USD 33.9 million in 2024 and is expected to reach USD 43.6 million by 2033.
- The Norway market is expected to grow at a CAGR of 2.9% from 2025 to 2033.
- In terms of segment, topical was the largest revenue generating treatment in 2024.
- Topical is the most lucrative treatment segment registering the fastest growth during the forecast period.
Onychomycosis market data book summary
| Market revenue in 2024 | USD 33.9 million |
| Market revenue in 2033 | USD 43.6 million |
| Growth rate | 2.9% (CAGR from 2025 to 2033) |
| Largest segment | Topical |
| Fastest growing segment | Topical |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oral, Topical |
| Key market players worldwide | GSK PLC, Abbott Laboratories, Pfizer Inc, Bausch Health Companies Inc, Bayer AG, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, Merck & Co Inc, Novartis AG ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Norway accounted for 0.9% of the global onychomycosis market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany onychomycosis market is projected to lead the regional market in terms of revenue in 2033.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 203.1 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Onychomycosis Market Scope
Onychomycosis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://www.sunpharma.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Cipla Ltd DR | View profile | 38955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | https://www.cipla.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Norway onychomycosis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to onychomycosis market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 36.58% in 2024. Horizon Databook has segmented the Norway onychomycosis market based on oral, topical covering the revenue growth of each sub-segment from 2021 to 2033.
The increasing population aged 65 & above in the country is boosting the prevalence of targeted diseases, creating new opportunities for market stakeholders. According to an article published by Oxford Academic in December 2022, in Norway, around 16% of the people were aged 67 or above by the end of 2021.
Furthermore, the country's residents aged 65 or older are projected to double by 2075. In addition, onychomycosis mostly occurs among the elderly population due to poor peripheral circulation, slower nail growth, and suboptimal immune function.
Thus, the rising geriatric population in the country is expected to raise the incidence of onychomycosis. Global companies are partnering with industry participants to leverage lucrative opportunities in the onychomycosis market in Norway.
Reasons to subscribe to Norway onychomycosis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway onychomycosis market databook
-
Our clientele includes a mix of onychomycosis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway onychomycosis market , including forecasts for subscribers. This country databook contains high-level insights into Norway onychomycosis market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Norway onychomycosis market size, by treatment, 2021-2033 (US$M)
Norway Onychomycosis Market Outlook Share, 2024 & 2033 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
